The Phase 3 clinical trial investigating Orforglipron (LY3502970) in Japanese adult participants with obesity disease reached its primary completion on 2025-06-19. This study (NCT05931380) evaluated the efficacy and safety of once-daily oral orforglipron.

Background

Obesity is a complex, chronic disease defined by excessive body fat, which can significantly impair health. It is associated with a range of serious health complications, including type 2 diabetes, cardiovascular diseases, certain types of cancer, and musculoskeletal disorders. The global prevalence of obesity has been rising, posing a substantial public health challenge worldwide, including in Japan. Effective management strategies are crucial for mitigating the long-term health risks and improving the quality of life for individuals living with obesity. Current treatments often involve lifestyle interventions, pharmacotherapy, and bariatric surgery, with ongoing research focused on developing new and more effective therapeutic options.

Trial design

This completed study (NCT05931380) is a Phase 3 trial that enrolled 238 participants. The study focused on Japanese adult participants with Obesity disease, specifically those with obesity-related health problems. The trial's main purpose was to investigate the efficacy and safety of oral orforglipron, administered once daily, compared to placebo.

What this means

The primary completion of this Phase 3 trial indicates that the main data collection period for the study's primary objectives has concluded. While no efficacy or safety results are available at this time, this milestone is a necessary step before data analysis and potential public disclosure of findings regarding orforglipron for obesity in Japanese adults. The completion suggests progress towards understanding the potential role of this oral GLP-1 receptor agonist in obesity management.

Source

Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05931380, titled "A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease," was recorded with a primary completion date of 2025-06-19 on clinicaltrials.gov.